Home › Triple-Negative Breast Cancer › North Carolina › Durham
Triple-Negative Breast Cancer clinical trials in Durham, NC
12 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Durham (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- Duke University, Durham
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RecruitingPhase 2
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi away
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
- Duke Cancer Institute, Durham
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
RecruitingPhase 2
- Duke University, Durham
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RecruitingPhase 2/3
- Duke Cancer Institute, Durham
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
RecruitingPhase 2
- Duke University Medical Center, Durham
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
RecruitingPhase 1
- University of North Carolina, Chapel Hill · 10 mi away
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RecruitingPhase 1
- Duke Cancer Institute /ID# 276267, Durham
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RecruitingPhase 2
- The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi away
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
RecruitingPhase 2
- University of North Carolina, Chapel Hill · 10 mi away
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
RecruitingPhase 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- University of North Carolina, Chapel Hill · 10 mi away
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Other studies in Durham
- Breast Cancer64 studies
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer39 studies
- Multiple Myeloma37 studies
- Acute Myeloid Leukemia33 studies
- Metastatic Cancer33 studies
- Prostate Cancer32 studies
- Lung Cancer32 studies
- Colorectal Cancer28 studies
- Ovarian Cancer27 studies
- Chronic Lymphocytic Leukemia27 studies
- Heart Failure26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.